HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
Public ClinicalTrials.gov record NCT03560258. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluated the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons who were on antiretroviral therapy (ART). The study aimed to induce potent virus-specific cytotoxic T lymphocytes (CTL) responses.
Study identification
- NCT ID
- NCT03560258
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- p24CE1/2 pDNA vaccine Biological
- p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine Biological
- Full-length p55^gag pDNA vaccine Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 26, 2019 (Actual)
- Primary completion
- Feb 10, 2021 (Actual)
- Completion
- Feb 10, 2021 (Actual)
- Last update posted
- Apr 26, 2022
2019 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS | Birmingham | Alabama | 35294 | — |
| UCLA CARE Center CRS | Los Angeles | California | 90035 | — |
| Ucsf Hiv/Aids Crs | San Francisco | California | 94110 | — |
| Northwestern University CRS | Chicago | Illinois | 60611 | — |
| Rush University CRS | Chicago | Illinois | 60612 | — |
| Massachusetts General Hospital CRS (MGH CRS) | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS | Boston | Massachusetts | 02115 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS | Rochester | New York | 14642 | — |
| Chapel Hill CRS | Chapel Hill | North Carolina | 27599 | — |
| Ohio State University CRS | Columbus | Ohio | 43210 | — |
| Penn Therapeutics, CRS | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics (VT) CRS | Nashville | Tennessee | 37204 | — |
| University of Washington AIDS CRS | Seattle | Washington | 98104-9929 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03560258, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2022 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03560258 live on ClinicalTrials.gov.